Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

The findings, highlighted across five posters, underscored significant advancements in achieving functional cures for chronic ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

The Knox County Health Department shared in a press release that each May, the United States observes Hepatitis Awareness Month to bring attention to viral hepatitis and ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.